Acute Lymphoblastic Leukemia, Version 2.2024

Bijal Shah, Ryan J. Mattison, Ramzi Abboud, Peter Abdelmessieh, Ibrahim Aldoss, Patrick W. Burke, Daniel J. DeAngelo, Shira Dinner, Amir T. Fathi, Jordan Gauthier, Michael Haddadin, Nitin Jain, Brian Jonas, Suzanne Kirby, Michaela Liedtke, Mark Litzow, Aaron Logan, Meixiao Long, Selina Luger, James K. ManganStephanie Massaro, William May, Olalekan Oluwole, Jae Park, Amanda Przespolewski, Sravanti Rangaraju, Caner Saygin, Marc Schwartz, Paul Shami, Benjamin Tomlinson, Jonathan Webster, Ajibola Awotiwon, Katie Stehman

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for acute lymphoblastic leukemia (ALL) provide recommendations for management of ALL, with a focus on the classification of ALL subtypes based on immunophenotype and cytogenetic/molecular markers; risk assessment and stratification for risk-adapted therapy; treatment strategies for Philadelphia chromosome (Ph)-positive and Ph-negative ALL for both adolescent and young adult and adult patients; and supportive care considerations. This selection from the NCCN Guidelines for ALL focuses on treatment recommendations for adults with newly diagnosed Ph-negative ALL based on current evidence.

Original languageEnglish
Pages (from-to)563-576
Number of pages14
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume22
Issue number8
DOIs
StatePublished - Oct 2024

Fingerprint

Dive into the research topics of 'Acute Lymphoblastic Leukemia, Version 2.2024'. Together they form a unique fingerprint.

Cite this